The agonist anti-GITR antibody DTA-1 induced regression of small established B16 melanoma tumours by impairing the accumulation of T-regs in the TME through downregulating foxp3 expression and enhanced tumour-specific CD8+ T-cell activity [103]. This evidence concerns the gene CD8A and melanoma.